Navigation Links
EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States
Date:9/30/2009

ing MS (patients who have experienced a first clinical event suggestive of MS). This trial was announced in September 2008.
  • The ONWARD (Oral Cladribine Added ON To Interferon beta-1a in Patients With Active Relapsing Disease) study: a Phase II placebo-controlled trial designed primarily to evaluate the safety and tolerability of adding cladribine tablets treatment to patients with relapsing forms of MS, who have experienced breakthrough disease while on established interferon-beta therapy. This trial was announced in January 2007.
  • Cladribine tablets have been granted a fast track designation by the US Food and Drug Administration based on the need for an oral therapy in a subset of patients with relapsing forms of multiple sclerosis.

    About multiple sclerosis

    Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that more than 2.5 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

    About EMD Serono, Inc.

    EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. The company has strong market positions in neurodegenerative diseases, with Rebif® (interferon beta-1a), as well as in endocrinology, with Saizen® (somatropin (rDNA origin) for injection) and Serostim® (somatropin (rDNA origin) for injection). EMD Serono is a leader in reproductive health, with Gonal-f® (follitropin alfa for injection), Luveris® (lutropin alfa for injection) and Ovidrel® Prefilled Syringe (chor
    '/>"/>

    SOURCE EMD Serono, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
    2. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
    3. Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
    4. Merck Seronos Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinsons Disease in a Phase III Pivotal Trial
    5. Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
    6. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
    7. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
    8. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
    9. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
    10. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
    11. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)... HARRISBURG, Pa. , Aug. 31, 2015 ... been reversed statewide since Pennsylvania ... the life-saving drug kits, naloxone. Heroin and ... in Pennsylvania , killing more individuals ... 2013, approximately 2,400 Pennsylvanians died from a drug overdose. ...
    (Date:8/31/2015)... DIEGO , Aug. 31, 2015 Regen ... today development of a novel means of delivering ... acid, RGBP-248, to liver tumors utilizing a clinically ... development overcomes previous hurdles with gene silencing therapeutics ... be delivered throughout the whole body.  By utilizing ...
    (Date:8/31/2015)... PRINCETON, N.J. , Aug. 31, 2015  /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today it has ... by the Data Review Committee (DRC) earlier this ... SGX942.  SGX942 is a first-in-class innate defense regulator ...
    Breaking Medicine Technology:Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6
    ... May 18, 2011 Oclaro, Inc. (NASDAQ: ... communications and laser solutions, today outlined its complete line ... of future products.  As a leading provider of diodes ... leverage its world-class manufacturing operations, technology expertise and packaging ...
    ... 18, 2011 Cempra Pharmaceuticals Inc. today announced that Prabhavathi ... two upcoming investor conferences in Paris.  Dr. Fernandes will present ... a.m. CET, May 24, at the Hilton Arc de Triomphe. ... at 3:00 p.m. CET, May 24, at the Paris ...
    Cached Medicine Technology:Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 2Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 3Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris 2
    (Date:8/31/2015)... ... September 01, 2015 , ... Neuropsychiatric ... injury with emphasis on transcranial near-infrared laser phototherapy ”. , As corresponding author ... has been largely untreatable - with mostly palliative treatments only - and now ...
    (Date:8/31/2015)... ... ... Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center is celebrating ... surgical and non-surgical disorders of the leg, ankle and foot. He also specializes ... , Dr. Paul Kovatis completed his orthopedic leg, ankle and foot fellowship training at ...
    (Date:8/31/2015)... ... August 31, 2015 , ... Diablo Publications (DP), ... it has officially launched a new website and company identity ( diablopublications.com) . ... more closely aligned with the company’s strategic vision for growth and expansion over ...
    (Date:8/31/2015)... Cokato, MN (PRWEB) , ... August 31, 2015 , ... ... and new product introductions: The Terrace Outdoor Sauna. After months of extensive engineering and ... attractive sauna model built to withstand the elements and is offered at a very ...
    (Date:8/31/2015)... ... 2015 , ... Wyoming Medical Center, an acute care hospital ... Documentation Improvement (CDI) and medical coding needs. Based on a proprietary Natural Language ... an enterprise-level coding solution that combines CDI, Coding, Quality and Compliance Auditing modules ...
    Breaking Medicine News(10 mins):Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Say “Hello” to the Brand New Finnleo Terrace Outdoor Saunas 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 3Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 4
    ... Are Ignoring the Fight Against Cancer, CLEVELAND, ... took the stage for a final debate before ... matters important to the,American public but fell short ... cancer is an issue identified by 62 percent ...
    ... Clinton Defends Healthcare Plan Built on Extending Customers and ... Revenue of Private Insurance ... Moore,participated in a press conference call today organized by ... from the movie SiCKO, including Reggie Cervantes, a,9/11 rescue ...
    ... Aflac Incorporated,(NYSE: AFL ) announced today that ... 29th Annual Institutional Investors Conference. President and Chief,Financial ... he is scheduled to make a presentation on ... Incorporated presentation, Mr. Cloninger will discuss the,company,s outlook ...
    ... of the worlds pre-eminent experts in urogynecology at Oregon Health ... the National Institutes of Health to study the extent of ... , The pelvic floor comprises the muscle group that ... injury, which is caused by damage to pelvic muscles or ...
    ... Citing a Center for,Medicare and Medicaid Services (CMS) ... 20 percent of national health care spending by,2017, ... statement,urging the House to take up legislation introduced ... (D-Md.) to safeguard Medicare:, "Looking at this ...
    ... -- Millions of cancer patients take drugs to boost ... anemic after chemotherapy. But a new study by Northwestern ... erythropoiesis-stimulating agents (ESAs), actually raise patients, risk of death, ... , A meta-analysis of 51 trials with 13,613 patients ...
    Cached Medicine News:Health News:Democratic Candidates Miss Key Health Issue in Debate 2Health News:Michael Moore Defends 9/11 Rescue Workers and Criticizes Insurance Industry on California Nurses Association Press Call 2Health News:Aflac Incorporated to Present at the Raymond James 29th Annual Institutional Investors Conference 2Health News:NIH awards OHSU researcher $1.2 million to determine causes of, risk factors for pelvic floor injury 2Health News:Blunt Cites New CMS Report in Calling for Action on Safeguarding Medicare 2Health News:Drug for anemic cancer patients raises risk of death 2Health News:Drug for anemic cancer patients raises risk of death 3
    The COBE 2991 Cell Processor provides reliable, automated cell processing, with the control you need to get reproducible results in your lab. This versatile machine offers users reliability and multi...
    The Wallac Multipette is used with 5 mL or 2.5 mL Combitips....
    The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
    ... lightweight and balanced for smooth, one-handed control. ... comfort, reducing fatigue in even the longest ... physician to easily steer the catheter through ... one finger. Reflexion's auto-lock technology keeps the ...
    Medicine Products: